Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874057 | 0.78 | ADORA3 (0.37) | CYP19A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL19075476 | 0.76 | ALDH1A1 (0.42) | CYP19A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL19244916 | 0.76 | HSD17B1 (0.47) | CYP19A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL14814651 | 0.76 | MAPT (0.41) | CYP19A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL713663 | 0.72 | CYP19A1 (0.55) | CYP19A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2155406 | 0.68 | CYP19A1 (0.40) | CYP19A1 | |
| SCHEMBL5561901 | 0.64 | SNCA (0.51) | MAPTSNCA | |
| SCHEMBL1521828 | 0.63 | — | — | |
| SCHEMBL533699 | 0.61 | RAB9A (0.44) | MAPT | |
| SCHEMBL32679828 | 0.61 | CYP19A1 (0.66) | CYP19A1ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906556-B2 | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1937638-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7385085-B2 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1802574-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ETHANOL CYCLICAMINE DERIVATIVES ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | CYP19A1 2662/4885ADORA3 1948/4885ADORA2A 3120/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | CYP19A1 3927/4885ADORA3 1661/4885ADORA2A 2283/4885 |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ASPH, DNPEP, APP | CYP19A1 1461/4885ADORA3 2451/4885ADORA2A 2641/4885 |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | APP, DNPEP, ASPH | CYP19A1 3031/4885ADORA3 3201/4885ADORA2A 3131/4885 |
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | AMY1A, AMY2A, DNPEP | CYP19A1 3434/4885ADORA3 3872/4885ADORA2A 3128/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | CYP19A1 3867/4885ADORA3 2995/4885ADORA2A 3177/4885 |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | DNPEP, ASPH, APP | CYP19A1 3203/4885ADORA3 2689/4885ADORA2A 3228/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | CYP19A1 3927/4885ADORA3 1661/4885ADORA2A 2283/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | CYP19A1 3927/4885ADORA3 1661/4885ADORA2A 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.